Prosztatarák: vizsgálatok itt: Mexikó

In Mexikó 12 Also abroad 1481

12 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.

2. fázisTaking people
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Where
Mexico City, Monterrey, Oaxaca City
Életkor
18 év and over
People
430 worldwide
Run by
Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00
2. fázisTaking people
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Benito Juárez, León, Mexico City
Életkor
18 év and over
People
100 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07287150 · EU 2025-521327-67-00
3. fázisTaking people
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Where
Guadalajara, Mérida, Mexico City, Monterrey
Életkor
18 év and over
People
1310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00
3. fázisTaking people
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Where
Guadalajara, Mexico City, Monterrey, Oaxaca City, Pachuca
Életkor
18 év and over
People
1440 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00
3. fázisTaking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
Huxquilucan, Mexico City
Életkor
18 év to 100 év
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
3. fázisTaking people
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Where
Guadalajara, Mexico City, Monterrey, Tlalpan
Életkor
18 év and over
People
1314 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00
3. fázisTaking people
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Where
Mexico City
Életkor
18 év to 100 év
People
940 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06855277
1/2. fázisTaking people
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Where
Tlalpan
Életkor
18 év and over
People
188 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00
3. fázisTaking people
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Where
Mexico City
Életkor
18 év and over
People
1273 worldwide
Run by
SWOG Cancer Research Network
See details and how to joinNCT03678025
2/3. fázisTaking people
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Where
Huxquilucan, Mexico City
Életkor
18 év to 100 év
People
443 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06780670 · EU 2024-512342-42-00
No phaseTaking people
A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer
Where
Mexico City
Életkor
18 év and over
People
300 worldwide
Run by
Memorial Sloan Kettering Cancer Center
See details and how to joinNCT07225309
3. fázisTaking people
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Where
Mexico City
Életkor
18 év and over
People
830 worldwide
Run by
Canadian Cancer Trials Group
See details and how to joinNCT06592924